Nyxoah Secures $110M Funding to Accelerate Genio U.S. Launch
NYXH•Nyxoah closed a $95 million equity financing complemented by a $15 million European Investment Bank loan tranche, totaling $110 million to fund Genio's U.S. commercial launch. The company has deployed 40 U.S. sales representatives under a new leadership team to accelerate Genio adoption among obstructive sleep apnea patients.
1. Capital Raise Details
Nyxoah completed a $95 million equity financing with strong insider participation and expects to draw a $15 million second tranche from its European Investment Bank loan by end-June 2026, providing an aggregate $110 million in new capital to accelerate growth.
2. U.S. Commercial Launch Plan
The company plans to deploy this capital to expand U.S. Genio commercialization, leveraging its team of 40 dedicated sales representatives supported by an experienced U.S.-based commercial leadership structure to build market penetration in obstructive sleep apnea therapy.
3. Leadership and Insider Participation
Strong participation from new and existing investors underscores confidence in Genio technology; management highlights this funding as a strategic milestone that secures Nyxoah's financial foundation for long-term value creation and supports sustained U.S. sales ramp and product adoption.
